References
- Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol 2010;2010:608751.
- International Diabetes Federation, Diabetes Atlas. 5th ed. Brussels, Belgium: International Diabetes Federation; 2011:1–14.
- Moreau KL, King JA. Protein misfolding and aggregation in cataract disease and prospects for prevention. Trends Mol Med 2012;18:273–82.
- Saraswat M, Suryanarayana P, Reddy PY, et al. Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. Mol Vis 2010;16:1525–37.
- Bloemendal H, de Jong W, Jaenicke R, et al. Ageing and vision: structure, stability and function of lens crystallins. Prog Biophys Mol Biol 2004;86:407–85.
- Luthra M, Balasubramanian D. Nonenzymatic glycation alters protein structure and stability. A study of two eye lens crystallins. J Biol Chem 1993;268:18119–27.
- Chen M, Curtis TM, Stitt AW. Advanced glycation end products and diabetic retinopathy. Curr Med Chem 2013;20:3234–40.
- Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005;67:3–21.
- Sharma KK, Santhoshkumar P. Lens aging: effects of crystallins. Biochim Biophys Acta 2009;1790:1095–108.
- Harding JJ. Viewing molecular mechanisms of ageing through a lens. Ageing Res Rev 2002;1:465–79.
- Swamy MS, Tsai C, Abraham A, Abraham EC. Glycation mediated lens crystallin aggregation and cross-linking by various sugars and sugar phosphates in vitro. Exp Eye Res 1993;56:177–85.
- Obrosova IG, Chung SS, Kador PF. Diabetic cataracts: mechanisms and management. Diabetes Metab Res Rev 2010;26:172–80.
- Murata M, Ohta N, Sakurai S, et al. The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis). Chem Biol Interact 2001;130–132:617–25.
- Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. Scientific World J 2013;2013:162750.
- Stefek M. Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract. Interdiscip Toxicol 2011;4:69–77.
- Kumar PA, Kumar MS, Reddy GB. Effect of glycation on alpha-crystallin structure and chaperone-like function. Biochem J 2007;408:251–8.
- Moghaddam MS, Kumar PA, Reddy GB, Ghole VS. Effect of diabecon on sugar-induced lens opacity in organ culture: mechanism of action. J Ethnopharmacol 2005;97:397–403.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–75.
- Uchida K, Kanematsu M, Sakai K, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 1998;95:4882–7.
- Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 2010;27:796–810.
- Birla SS, Gaikwad SC, Gade AK, Rai MK. Rapid synthesis of silver nanoparticles from Fusarium oxysporum by optimizing physicocultural conditions. Scientific World J 2013;2013:796018.
- Gacche RN, Dhole NA. Profile of aldose reductase inhibition, anti-cataract and free radical scavenging activity of selected medicinal plants: an attempt to standardize the botanicals for amelioration of diabetes complications. Food Chem Toxicol 2011;49:1806–13.
- Gond DS, Meshram RJ, Jadhav SG, et al. In silico screening of chalcone derivatives as potential inhibitors of dihydrofolate reductase: assessment using molecular docking, paired potential and molecular hydrophobic potential studies. Drug Invent Today 2013;5:182–191.
- Kadam A, Dawane B, Pawar M, et al. Development of novel pyrazolone derivatives as inhibitors of aldose reductase: an eco-friendly one-pot synthesis, experimental screening and in silico analysis. Bioorg Chem 2014;53:67–74.
- Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
- Steuber H, Zentgraf M, Gerlach C, et al. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. J Mol Biol 2006A;363:174–87.
- Miteva MA, Guyon F, Tufféry P. Frog2: Efficient 3D conformation ensemble generator for small compounds. Nucleic Acids Res 2010;38:W622–7.
- Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. J Comput Chem 2007;28:1145–52.
- Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639–1662.
- Gacche RN, Meshram RJ, Shegokar HD, et al. Flavonoids as a scaffold for development of novel anti-angiogenic agents: an experimental and computational enquiry. Arch Biochem Biophys 2015;577-578:35–48.
- Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011;51:2778–86.
- Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8:127–34.
- Ramana BV, Raju TN, Kumar VV, Reddy PU. Defensive role of quercetin against imbalances of calcium, sodium, and potassium in galactosemic cataract. Biol Trace Elem Res 2007;119:35–41.
- Harrington V, Srivastava OP, Kirk M. Proteomic analysis of water insoluble proteins from normal and cataractous human lenses. Mol Vis 2007;13:1680–94.
- Dalle-Donne I, Rossi R, Giustarini D, et al. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003;329:23–38.
- Negre-Salvayre A, Salvayre R, Augé N, et al. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 2009;11:3071–109.
- Stitt AW, Curtis TM. Diabetes-related adduct formation and retinopathy. J Ocul Biol Dis Infor 2011;4:10–18.
- Cervantes-Laurean D, Schramm DD, Jacobson EL, et al. Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. J Nutr Biochem 2006;17:531–40.
- Wu CH, Yen GC. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J Agric Food Chem 2005;53:3167–73.
- Adrover M, Mariño L, Sanchis P, et al. Mechanistic insights in glycation-induced protein aggregation. Biomacromolecules 2014;15:3449–62.
- Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 2011;585:2424–30.
- Meng F, Abedini A, Plesner A, et al. The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 2010;49:8127–33.
- Matsuda H, Morikawa T, Toguchida I, Yoshikawa M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem Pharm Bull (Tokyo) 2002;50:788–95.
- Meyer AG, Sawyer SL, Ellington AD, Wilke CO. Analyzing machupo virus-receptor binding by molecular dynamics simulations. Peer J 2014;2:e266.
- Osajima T, Suzuki M, Neya S, Hoshino T. Computational and statistical study on the molecular interaction between antigen and antibody. J Mol Graph Model 2014;53:128–39.
- Weng C, Fu Y, Jiang H, et al. Binding interaction between a queen pheromone component HOB and pheromone binding protein ASP1 of Apis cerana. Int J Biol Macromol 2015;72:430–6.
- Cousido-Siah A, Ruiz FX, Mitschler A, et al. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design. Acta Crystallogr D Biol Crystallogr 2014;70:889–903.
- Podjarny A, Cachau RE, Schneider T, et al. Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding. Cell Mol Life Sci 2004;61:763–73.
- Koch C, Heine A, Klebe G. Tracing the detail: how mutations affect binding modes and thermodynamic signatures of closely related aldose reductase inhibitors. J Mol Biol 2011;406:700–12.
- Steuber H, Zentgraf M, Podjarny A, et al. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. J Mol Biol 2006B;356:45–56.
- Wilson DK, Tarle I, Petrash JM, Quiocho FA. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci USA 1993;90:9847–51.